SEC Form 4 · accession 0001140361-15-023539
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
Jun 4, 2015
Accepted (ET)
Jun 8, 2015 · 6:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 4, 2015 | F | 1,801 | $120.46 | D | 29,878 | D | |
| Common StockF1,F2 | Jun 5, 2015 | S | 1,649 | $122.2978 | D | 28,229 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on March 11, 2015.
- F2The price in column 4 is a weighted average price. The price actually received ranged from $120.25 to $123.86. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.